ALISO VIEJO, Calif., Feb. 7, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2012.
Quarterly Financial Highlights
Total company net revenues increased to $16.5 million, representing growth of 22% versus the previous quarter Gross and net NUEDEXTA® sales increased to $18.4 million and $14.9 million, respectively, representing growth of 19% and 20% versus the previous quarter
